Article Text

Download PDFPDF
Mechanism of action of vedolizumab: do we really understand it?

Statistics from Altmetric.com

Footnotes

  • Contributors GR has written the commentary.

  • Competing interests GR has consulted to AbbVie, Augurix, Calypso, Celgene, FALK, Ferring, Essex/MSD, Genentech, Janssen, Lilly, Novartis, Pfizer, Roche, UCB, Takeda, Tillotts, Vifor and Zeller. GR has received speaker’s honoraria from AbbVie, FALK, Ferring, MSD, Pfizer, Phadia, Takeda, Tillotts, UCB and Vifor, and received educational grants and research grants from AbbVie, Ardeypharm, FALK, Flamentera, Novartis, MSD, Pfizer, Roche, Takeda, Tillotts, UCB and Zeller.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Inflammatory bowel disease
    Sebastian Zeissig Elisa Rosati C Marie Dowds Konrad Aden Johannes Bethge Berenice Schulte Wei Hung Pan Neha Mishra Maaz Zuhayra Marlies Marx Maren Paulsen Anne Strigli Claudio Conrad Dörthe Schuldt Anupam Sinha Henriette Ebsen Sabin-Christin Kornell Susanna Nikolaus Alexander Arlt Dieter Kabelitz Mark Ellrichmann Ulf Lützen Philip C Rosenstiel Andre Franke Stefan Schreiber